title: A novel method for managing water and electrolyte balance after transsphenoidal surgery: preliminary study of moderate water intake restriction.
abstract: Hyponatremia is a common and potentially serious complication of transsphenoidal surgery (TSS). Since September 2009, we have implemented moderate water intake restriction (< 2500 mL/day) after TSS in an attempt to prevent this complication. The aim of this study was to investigate the efficacy of a combination of moderate restriction of water intake plus antidiuretic hormone (arginine vasopressin [AVP]) replacement therapy in patients with diabetes insipidus (DI) for reducing the incidence of delayed hyponatremia after TSS. Patients treated from September 2005 to August 2009 were allowed to drink water freely after surgery (the control group), while patients treated from September 2009 to June 2012 were restricted to less than 2500 mL water per day (the water restriction group). To reduce the occurrence of hypernatremia, AVP replacement therapy was provided immediately after the development of DI. We retrospectively analyzed the incidence of hyponatremia, DI, and hypernatremia in patients following TSS. Hyponatremia incidence was significantly lower in the water restriction group (P = 0.017); however, there were no significant differences in DI incidence and hypernatremia incidence between the 2 groups. Under DI control with AVP replacement therapy, the water restriction group showed no significant difference in the daily self-rated thirst level for the patients with and without DI. Moderate water intake restriction in addition to AVP replacement therapy significantly decreases the incidence of hyponatremia without patient discomfort (extreme thirst) and other complications. However, further studies are required to determine the most effective amount of water and the optimal duration of postoperative water restriction.
authors.forename: Kazuhito
authors.initials: K
authors.lastname: Takeuchi
authors.forename: Tetsuya
authors.initials: T
authors.lastname: Nagatani
authors.forename: Eriko
authors.initials: E
authors.lastname: Okumura
authors.forename: Toshihiko
authors.initials: T
authors.lastname: Wakabayashi
mesh_terms: D000328:Adult; D000368:Aged; D050034:Antidiuretic Agents / Q000627:therapeutic use; D001127:Arginine Vasopressin / Q000627:therapeutic use; D003131:Combined Modality Therapy; D003919:Diabetes Insipidus / Q000188:drug therapy / Q000209:etiology / Q000503:physiopathology; D004326:Drinking; D004724:Endoscopy / Q000009:adverse effects*; D005260:Female; D006801:Humans; D006955:Hypernatremia / Q000175:diagnosis / Q000209:etiology / Q000503:physiopathology / Q000517:prevention & control; D007010:Hyponatremia / Q000175:diagnosis / Q000209:etiology / Q000503:physiopathology / Q000517:prevention & control*; D008297:Male; D008875:Middle Aged; D010911:Pituitary Neoplasms / Q000473:pathology / Q000601:surgery*; D012189:Retrospective Studies; D013101:Sphenoid Sinus / Q000601:surgery*; D013997:Time Factors; D016896:Treatment Outcome; D014868:Water Deprivation; D014882:Water-Electrolyte Balance / Q000187:drug effects
chemical_list: D050034:Antidiuretic Agents; D001127:Arginine Vasopressin